webinar
Optimizing antibody leads in early drug discovery with key developability insights
5 June 2025 | By WuXi Biologics
Stop costly biologic failures. This masterclass reveals high-throughput strategies to optimize antibody leads upfront.
List view / Grid view
Hit-to-Lead
news
High-throughput NaV1.9 assay to advance pain therapies
Metrion Biosciences has introduced a breakthrough NaV1.9 screening assay, aimed at overcoming historical challenges in pain research and advancing the development of non-opioid treatments.
webinar
Advancing ADC Development: End-to-End Solutions from Design to Characterization
4 April 2025 | By Eurofins Discovery
Dr. Francisca Neethling from Eurofins Discovery explores the comprehensive process of ADC development, covering payload linker design, optimization, and the bioanalytical and functional characterization of ADC molecules.
webinar
Reprogramming immunity: designing smarter checkpoint receptor agonists
19 March 2025 | By Eurofins DiscoverX
Join Dr Daniela Cipolletta from Seismic Therapeutic to discover how FcγRIIb clustering enabled the discovery of S-4321, a low-affinity PD-1 agonist that restores immune balance by engaging multiple inhibitory pathways.
webinar
Advancing obesity drug discovery: Cell-based assays for GLP-1 and the G-Suite
9 January 2025 | By Eurofins DiscoverX
Gain valuable insights into the latest advancements in obesity drug discovery and enhance your research capabilities.
webinar
CRISPR™ MDCKII cell lines development for bioavailability and DDI assessments
17 July 2024 | By Eurofins Discovery
Join this webinar to hear from Eurofins Discovery on the latest offerings for drug-drug interaction assessments using CRISPR KO/KI MDCKII cell lines
news
Discovery of a promising agonist adjuvant
PVP-037, identified through a small molecule screen, induces a more durable and broader immune response to vaccines.
webinar
The value of GPCR cell-based assays in drug discovery
20 June 2024 | By Eurofins DiscoverX
Join this webinar to discover how GPCR functional, cell-based assays determine off-target effects, reveal safety issues, and define drug mechanism of action to ultimately evaluate the therapeutic potential of candidate molecules.
whitepaper
Poster: Assays for DDX3, DDX5, DDX17, RIG-I, and MDA5
A panel of HTS assays was developed using the Transcreener platform to accelerate the development of selective helicase inhibitors.
whitepaper
Poster: Assays for PRMT5, MLL4, METTL3/14, & NSP14
AptaFluor SAH: A Homogenous, Universal Assay for Histone, RNA, & DNA Methyltransferases. Case Study for PRMT5, MLL4, METTL3/14, & NSP14
webinar
SAFIRE: AI predicted ADME for drug discovery: leveraging BioPrint
9 April 2024 | By Eurofins Discovery
Join Dr Carleton Sage to learn about predicting ADME properties as a key approach to improving the efficiency of small molecule drug discovery. AI ADME model development approaches and case studies within drug discovery projects will be discussed.
video
Video: Dianthus for identifying Microcycle® hits
22 February 2024 | By Dr. Reece Gardner
Hear how Dr. Reece Gardner from Curve Therapeutics uses the Dianthus instrument with Spectral Shift technology to validate Microcycle® hits.
whitepaper
Whitepaper: Targeting kinases in the innate immune response
The guide provides examples of how Transcreener allowed rapid assay development to enable screening for kinases in innate immune pathways.
article
A Guide to DNA Damage Response and Innate Immunity
In this guide, we provide an overview of the DDR and innate immune pathway and describe Transcreener Assays and Assay Systems for key targets.
whitepaper
Article: Tips and Tricks for Leveraging Advanced Flow Cytometry
Tips and tricks for fully leveraging Advanced Flow Cytometry.
